Global Typhoid Vi Polysaccharide Vaccine Market Size By Type (Child, Adult), By Application (Government Institution, Private Sector), By Geographic Scope And Forecast

Typhoid Vi Polysaccharide Vaccine Market Size And Forecast

Typhoid Vi Polysaccharide Vaccine Market size was valued at USD 5.98 Billion in 2023 and is projected to reach USD 13.28 Billion by 2030, growing at a CAGR of 18.9% during the forecast period 2024-2030.

The Global Typhoid Vi Polysaccharide Vaccine Market is primarily driven by factors, including rising government initiatives, rising typhoid prevalence, growing immunization campaigns worldwide, and rising non-government vaccination initiatives. The Global Typhoid Vi Polysaccharide Vaccine Market report provides a holistic evaluation of the market. The report thoroughly analyzes important segments, trends, drivers, restraints, competitive landscape, and factors that play a substantial role in the market.

Global Typhoid Vi Polysaccharide Vaccine Market Drivers

The market drivers for the Typhoid Vi Polysaccharide Vaccine Market can be influenced by various factors. These may include

• Typhoid Fever Prevalence The need for the vaccination is anticipated to be driven by areas with a high occurrence of the disease. This includes places with low standards of cleanliness and hygiene, limited access to potable water, and densely populated housing.
• Government Immunisation Programmes Governmental efforts to lower the incidence of typhoid fever by means of immunisation campaigns have the potential to substantially propel market expansion. High-risk groups are frequently the focus of these initiatives, including children living in endemic areas and visitors to locations where typhoid is common.
• Traveller Immunisation As more people go abroad to places where typhoid is widespread, there is a greater need for the vaccine among those who want to avoid getting sick.
• breakouts and Epidemics As authorities work to stop the disease’s spread, recurring breakouts or epidemics of typhoid fever in particular areas may cause unexpected spikes in demand for the vaccine.
• Growing Awareness Demand for the vaccine may be influenced by rising public, medical professional, and policymaker awareness of the value of vaccination in preventing infectious diseases like typhoid.
• Technological Advancements New developments in vaccine production and development can result in more affordable, safer, and effective vaccines, which will open up new markets.
• Public Health Investments The market for typhoid vaccines may expand if governments, nonprofits, and international agencies make greater investments in public health infrastructure and programmes to fight infectious illnesses.
• Expanded Indications By include new age categories or populations at risk in the vaccine’s indications, coupled with advice from health authorities, the market for typhoid vaccinations can be expanded.
• Regulatory Support Positive regulatory frameworks, such as accelerated vaccination approval procedures and financial aid or other incentives from the government for vaccine producers, can propel market expansion.
• Global Health Priorities Typhoid fever might increase demand for the vaccine if it is included in agendas and initiatives related to global health, such as the World Health Organization’s efforts to control and eradicate diseases that can be prevented by vaccination.

Global Typhoid Vi Polysaccharide Vaccine Market Restraints

Several factors can act as restraints or challenges for the Typhoid Vi Polysaccharide Vaccine Market. These may includelimiting Accessibility and AffordabilityPoor healthcare facilities, insufficient distribution networks, and high vaccine costs can all contribute to limiting vaccine access in areas where typhoid fever is most common, impeding attempts to vaccinate as many people as possible.

• Competing Vaccines and Treatment Options If alternative typhoid vaccines (like the oral Ty21a vaccine) and treatment options (like antibiotics) are available, the demand for Vi polysaccharide vaccines may decline. This is especially true if the alternatives are thought to be more affordable or convenient.
• Vaccine Hesitancy Uncertainty about the safety of vaccines and a reluctance to accept them due to disinformation, cultural or religious objections, or other reasons, can limit market growth and impede vaccination adoption.
• Cold chain management problems Vi polysaccharide vaccines usually need to be transported and stored chilled, which presents logistical challenges. These challenges are particularly noticeable in settings with limited resources and inadequate cold chain infrastructure, which can impact the distribution and availability of vaccines.
• Vi polysaccharide vaccines may only provide temporary protection against typhoid fever, and they may need to be repeated on a regular basis to sustain immunity. This could complicate vaccination schedules and lower vaccination rates overall.
• Disease Epidemiology and Seasonality The erratic and seasonal character of typhoid fever outbreaks across various locations may influence vaccine demand, resulting in oscillations in market demand and possible vaccine supply overstocking or underutilization.
• Regulatory Obstacles Complying with complicated licencing and manufacturing standards, strict regulatory requirements, and protracted clearance procedures can make it difficult for vaccine producers to enter the market, especially if they operate in numerous jurisdictions.
• Geopolitical Factors and Conflict Zones In some areas, political unrest, hostilities, and humanitarian crises can cause disruptions to healthcare services, including immunisation programmes. This can lower the demand for vaccines and create logistical difficulties when delivering vaccines.
• Economic Restrictions Government spending on immunisation programmes and public health interventions may be limited by economic downturns, budgetary restrictions, and conflicting healthcare objectives. This could have an impact on the distribution and purchase of vaccines.
• Emerging Infectious illnesses The development of novel infectious illnesses or changing patterns of illness may cause resources and attention to be diverted from typhoid vaccination campaigns, which could have an adverse effect on the market’s expansion and typhoid vaccine investment.

Global Typhoid Vi Polysaccharide Vaccine Market Segmentation Analysis

The Global Typhoid Vi Polysaccharide Vaccine Market is Segmented on the basis of Type, Application, And Geography.

Typhoid Vi Polysaccharide Vaccine Market, By Type

• Child
• Adult

Based on Type, The market is classified into Child and Adult. The Child segment is expected to grow at a substantial pace owing to various government vaccination initiatives.

Typhoid Vi Polysaccharide Vaccine Market, By Application

• Government Institution
• Private Sector
• Others

Based on Application, The market is segmented into Government Institution, Private Sector, and Others.The Government Institution segment dominates the market and is predicted to grow quickly during the forecast period.

Typhoid Vi Polysaccharide Vaccine Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world

Based on Geography, The market is segmented into North America, Europe, Asia Pacific, and the Rest of the world. Due to countries such as India, Pakistan, and Bangladesh being endemic to typhoid and having a high demand for typhoid vaccines, the Asia Pacific is predicted to be the most attractive area for market growth.

Key Players

With an emphasis on the global market, the “Global Typhoid Vi Polysaccharide Vaccine Market” study report will offer insightful information. The prominent players in the market are Johnson & Johnson Private Limited (US), Bio Farma (Indonesia), Takeda Pharmaceutical Company Limited (Japan), Pfizer Inc. (US), Mallinckrodt (US), Novartis AG (Switzerland), EMERGENT (US), Sun Pharmaceutical Industries Ltd. (India), Bharat Biotech (India), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), AstraZeneca (UK), GlaxoSmithKline plc (UK), Mylan N.V. (US), J Merck & Co., Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux SA (France), and Amgen Inc. (US). The competitive landscape section includes key development strategies, market share analysis, and market positioning analysis of the aforementioned competitors internationally.

Key Developments

• On Apr 2022, To combat the rising prevalence of typhoid, Nepal introduced the Typhoid vaccine into routine immunization across the country.
• In Oct 2021, the Typhoid vaccine was found to be 84% effective in preventing the disease in children.

Report Scope

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes an in-depth analysis of the market from various perspectives through Porter’s five forces analysis• Provides insight into the marke